The company’s offerings include carbon steel, stainless steel, alloy steel, nickel, aluminum, and red metals in various shapes and forms.

In addition to the POWR Rating grades we have stated above, one can see PFE ratings for Momentum and Stability here.Ĭlick here to checkout our Healthcare Sector Report for 2021Ĭhicago-based RYI is an industrial metals processing and distributing company. It is ranked #8 out of 196 stocks in the Medical – Pharmaceuticals industry. PFE has a Growth grade of A, and a Value, Sentiment, and Quality grade of B. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree. The stock has an overall A rating, which equates to Strong Buy in our proprietary rating system. PFE’s strong fundamentals are reflected in its POWR Ratings. The stock has gained 44.1% in price year-to-date. And the $786.01 billion consensus revenue estimate for the coming year reflects a 6.4% year-over-year improvement. The Street’s $44.42 EPS estimate for the next year (fiscal 2022) indicates a 16.2% increase from the current year. Its adjusted income rose 132.7% from the prior-year quarter to $7.69 billion, while its adjusted EPS came in at $1.34, up 127.1% from the same period last year. Its 3.65 forward Price/Sales multiple is 47.9% lower than the 7.01 industry average.įor its fiscal third quarter, ended October 3, PFE’s revenue increased 134.4% year-over-year to $24.09 billion.

In terms of its forward non-GAAP P/E, PFE is currently trading at 12.6x, which is 41.1% lower than the 21.4x industry average.

The acquisition is expected to expand PFE’s portfolio and includes biologics to enhance the ability of the body’s immune system to detect and destroy cancer cells. On November 17, PFE announced its successful acquisition of an immune-oncology company, Trillium Therapeutics. This should add substantially to PFE’s revenue stream. On November 19, PFE and BNTX announced that the United States Food and Drug Administration (FDA) had expanded the emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine booster shots to include individuals aged 18 or older. The company developed the Pfizer-BioNTech COVID-19 vaccine with BioNTech SE ( BNTX). New York City-based PFE is a well-known developer and distributor of biopharmaceutical products that include medicines, vaccines, and other therapies.

Stock that will skyrocket